Prostate cancer cells treated with antiandrogenic drugs can develop castration-resistant prostate cancer (CRPC), a condition where tumor cells acquire the mechanisms for survival and proliferation independent of androgen receptor (AR) signaling, while androgen-dependent cells undergo apoptosis. This evidence concerns the gene AR and neoplasm.